Saccharomyces boulardii modulates dendritic cell properties and intestinal microbiota disruption after antibiotic treatment;Saccharomyces boulardii module les propriétés des cellules dendritiques et le déséquilibre du microbiote intestinal après un traitement antibiotique.

Gastroenterologie Clinique et Biologique

Volumn 34, Issue SUPPL. 1, 2010, Pages

  Collignon, A ^a,c   Sandre C ^b   Barc, M C ^a  

^a University Paris Sud   (France)

^b INSERM   (France)

^c HÔPITAL JEAN VERDIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CD86 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROBIOTIC AGENT; RNA 16S; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIGEN EXPRESSION; ARTICLE; BACTEROIDES; CELL ACTIVATION; CLINICAL EVALUATION; CLOSTRIDIUM; CLOSTRIDIUM COCCOIDES; CONFOCAL MICROSCOPY; DENDRITIC CELL; DIARRHEA; ENTEROBACTERIACEAE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HOMEOSTASIS; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIMARY IMMUNE RESPONSE; SACCHAROMYCES BOULARDII; UPREGULATION; ANIMAL; C3H MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; METABOLISM; METAGENOME; MOUSE; MOUSE STRAIN; SACCHAROMYCES; TREATMENT OUTCOME;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANIMALS; ANTI-BACTERIAL AGENTS; DENDRITIC CELLS; DIARRHEA; DISEASE MODELS, ANIMAL; IN SITU HYBRIDIZATION, FLUORESCENCE; METAGENOME; MICE; MICE, INBRED C3H; MICE, INBRED STRAINS; SACCHAROMYCES; TREATMENT OUTCOME;

EID: 77957358906     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(10)70024-5     Document Type: Article

References (18)

1. Czerucka D., Piche T., Rampal P. Review article: yeast as probiotics -Saccharomyces boulardii. Aliment Pharmacol Ther 2007, 26:767-778.
2. Elmer G.W., McFarland L.V., Surawicz C.M., Danko L., Greenberg R.N. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999, 13:1663-1668.
3. Surawicz C.M., McFarland L.V., Greenberg R.N., Rubin M., Fekety R., Mulligan M.E., et al. The search for a better treatment for recurrent Clostridium difficile disease: use a high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000, 31:1012-1017.
4. Buts J.P., Bernasconi P., Vaerman J.P., Dive C. Stimulation of secretory IgA and secretory component of immunoglobulin in small intestine of rats treated with Saccharomyces boulardii. Digest Dis Sci 1990, 35:251-256.
5. Qamar A., Aboudola S., Warny M., Michetti P., Pothoulakis C., LaMont J.T., et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001, 69:2762-2765.
6. Pothoulakis C., Kelly C.P., Joshi M.A., Gao N., O'Keane C.J., Castagliuolo I., et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993, 104:1108-1115.
7. Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., Pothoulakis C. Saccharomyces boulardii protease mediates Clostridium difficile toxins A and B effects in human colonic mucosa. Infect Immun 1999, 67:302-307.
8. Tasteyre A., Barc M.C., Karjalainen T., Bourlioux P., Collignon A. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathogen 2002, 32:219-225.
9. Sougioultzis S., Simeonidis S., Bhaskar K.R., Chen X., Anton P.M., Keates S., et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006, 343:69-76.
10. Suau A., Bonnet R., Sutren M., Godon J.J., Gibson G.R., Collins M.D., et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 1999, 65:4799-4807.
11. Sullivan A., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001, 1:101-114.
12. Barc M.C., Bourlioux F., Rigottier-Gois L., Charrin-Sarnel C., Janoir C., Boureau H., et al. Effect of amoxicillin-clavulanic acid on human fecal flora in a gnotobiotic mouse model assessed with fluorescence hybridization using group-specific 16S rRNA probes in combination with flow cytometry. Antimicrob Agents Chemother 2004, 48:1365-1368.
13. Wong W.C., Hentges D.J., Dougherty S.H. Adequacy of the human fecal microbiota associated mouse as a model for studying the ecology of the human intestinal tract. Microbial Ecol Health Dis 1996, 9:187-198.
14. Rigottier-Gois L., Le Bourhis A.G., Gramet G., Rochet V., Doré J. Fluorescent hybridisation combined with flow cytometry and hybridisation of total RNA to analyse the composition of microbial communities in human faeces using 16S rRNA probes. FEMS Microbiol Ecol 2003, 43:237-245.
15. Barc M.C., Charrin-Sarnel C., Rochet V., Bourlioux F., Sandré C., Boureau H., et al. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii. Anaerobe 2008, 14:229-233.
16. Bléhaut H., Massot J., Elmer G.W., Levy R.H. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Disp 1989, 10:353-364.
17. Nicaise P., Gleizes A., Sandre C., Kergot R., Lebrec H., Forestier F., et al. The intestinal microflora regulates cytokine production positively in spleen-derived macrophages but negatively in bone marrow-derived macrophages. Eur Cytokine Netw 1999, 10:365-372.
18. Thomas S., Przesdzing I., Metzke D., Schmitz J., Radbruch A., Baumgart D.C. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dentritic cells and T cell proliferation. Clin Exp Immunol 2009, 156:78-87.